Immunotherapy Maintains Ovarian Function in a Mouse Model of Breast Cancer

1

Triple negative breast cancer (TNBC) accounts for 15%-20% of breast cancer cases and is more common in reproductive-age women.
2

Chemotherapy for TNBC often leads to infertility and endocrine disruption, affecting many women undergoing treatment.
3

Immunotherapies targeting PD-1, LAG-3, and TIM-3 showed no negative impact on ovarian function or hormone levels in a TNBC mouse model.
4

The study suggests that immunotherapy may be a viable option for fertility-sparing treatment in women with TNBC.
5

Standard-of-care PD-1 inhibitors do not adversely affect ovarian architecture or hormone homeostasis in treated mice.

Frontiers In Reproductive Health

by Payton De La Cruz, Morgan F. Woodman-Sousa, Julia N. McAdams, Ellia Sweeney, Lola Hakim, Melanie Morales Aquino, Kathryn J. Grive
July 2, 2026

1